Shigella sonnei Vaccine Candidates WRSs2 and WRSs3 Are as Immunogenic as WRSS1, a Clinically Tested Vaccine Candidate, in a Primate Model of Infection

• Main Authors: Barnoy, S, Baqar, S, Kaminski, R W, Collins, T, Nemelka, K, Hale, T L, Ranallo, R T, Venkatesan, M M
• Format: Report
• Language: English
• Subjects: ASC(ANTIBODY SECRETING CELLS); ASSAYING; CELLS(BIOLOGY); ENDOTOXINS; ENTEROTOXINS; EPITHELIUM; GENES; GRAPHS; HUMORAL IMMUNITY; IMMUNOGLOBULINS; LIVE VACCINE CANDIDATES; Medicine and Medical Research; Microbiology; MONKEYS; Pharmacology; REPRINTS; RHESUS MONKEYS; SHIGELLA SONNEI; SHIGELLOSIS; TABLES(DATA); TOXICITY; VACCINES; WRSS2; WRSS3

Shigella causes diarrhea and dysentery through contaminated food and water. Shigella sonnei live vaccine candidates WRSs2 and WRSs3 are attenuated principally by the loss of VirG(IcsA) that prevents bacterial spread within the colonic epithelium. In this respect they are similar to the clinically tested vaccine candidate WRSS1. However, WRSs2 and WRSs3 are further attenuated by loss of senA, senB and WRSs3 also lacks msbB2. As previously shown in cell culture assays and in small animal models, these additional gene deletions reduced the levels of enterotoxicity and endotoxicity of WRSs2 and WRSs3, potentially making them safer than WRSS1. However the behavior of these second-generation VirG(IcsA)-based vaccine candidates in eliciting an immune response in a gastrointestinal model of infection has not been evaluated. In this study, WRSs2 and WRSs3 were nasogastrically administered to rhesus monkeys that were evaluated for colonization, as well as for systemic and mucosal immune responses. Both vaccine candidates were safe in rhesus monkeys and behaved comparably to WRSS1 in bacterial excretion rates that demonstrated robust intestinal colonization. Furthermore, humoral and mucosal immune responses elicited against bacterial antigens appeared similar in all categories across all three strains indicating that the additional gene deletions did not compromise the immunogenicity of these vaccine candidates. Based on data from previous clinical trials with WRSS1, it is likely that, WRSs2 and WRSs3 will not only be safer in human volunteers but will generate comparable levels of systemic and mucosal immune responses that were achieved with WRSS1. Published in Vaccine, 2011. The original document contains color images.